Article
Oncology
T. Yoshino, A. Cervantes, H. Bando, E. Martinelli, E. Oki, R. -H. Xu, N. A. Mulansari, K. Govind Babu, M. A. Lee, C. K. Tan, G. Cornelio, D. Q. Chong, L. -T. Chen, S. Tanasanvimon, N. Prasongsook, K. -H. Yeh, C. Chua, M. D. Sacdalan, W. J. Sow (Jenson), S. T. Kim, R. T. Chacko, R. A. Syaiful, S. Z. Zhang, G. Curigliano, S. Mishima, Y. Nakamura, H. Ebi, Y. Sunakawa, M. Takahashi, E. Baba, S. Peters, C. Ishioka, G. Pentheroudakis
Summary: The ESMO Guidelines for metastatic colorectal cancer (mCRC) were adapted to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for Asian patients. The guidelines were developed by a panel of experts from Asian oncological societies, based on scientific evidence and independent of treatment practices and reimbursement decisions. The aim is to optimize and harmonize the management of mCRC across Asia, considering the differences in screening practices, molecular profiling, and drug approvals and reimbursement strategies.
Article
Oncology
S. J. Strauss, A. M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J. Y. Blay, S. Bolle, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Alava, A. P. Dei Tos, X. Garcia Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, R. Ladenstein, P. G. Casali, S. Stacchiotti
Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L. -Y. Wu, W. Rajabto, K. Harano, S. -h. Hong, R. A. Malik, H. Strebel, I. M. Aggarwal, C. -H. Lai, T. Dejthevaporn, S. Tangjitgamol, W. F. Cheng, W. Y. Chay, D. Benavides, N. M. Hashim, Y. W. Moon, M. Yunokawa, T. D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis
Summary: The European Society for Medical Oncology (ESMO) published the most recent version of their guidelines for endometrial cancer in 2022. In order to account for variations in endometrial cancer management in Asia, a virtual meeting was held in July 2022 to adapt the ESMO guidelines. The guidelines represent the consensus opinion of Asian experts from various oncological societies. The aim is to provide guidance for the management of endometrial cancer in different regions of Asia, considering variations in clinical presentation, diagnostic practices, and access to treatment options.
Article
Oncology
T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis
Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L. K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis
Summary: To accommodate the specific requirements of prostate cancer treatment in Asia, a special meeting was convened by ESMO and SSO to revise the guidelines published in 2020. These guidelines represent the consensus opinions of prostate cancer treatment experts from Asian countries and aim to provide optimization and harmonization recommendations for the management of prostate cancer patients across different regions in Asia.
Review
Cell Biology
Omayma Mazouji, Abdelhak Ouhajjou, Roberto Incitti, Hicham Mansour
Summary: Colorectal cancer is one of the most common cancers globally, with solid biopsy being an essential guide for clinical management, but liquid biopsy has shown significant promise as an alternative tool in various CRC clinical applications, such as early detection, treatment decision-making, and monitoring treatment response.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
R. Kanesvaran, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis
Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.
Review
Genetics & Heredity
Yali Liu, Harry Cheuk-Hay Lau, Wing Yin Cheng, Jun Yu
Summary: Colorectal cancer (CRC) is a common and deadly form of cancer, with both genetic and environmental factors playing a role in its development. Dysbiosis in the gut microbiome has been identified as a risk factor for CRC. Recent data has shown that the gut microbiome is directly involved in DNA damage, inflammation, and drug resistance in CRC, suggesting that modulating the gut microbiome could be a powerful tool in prevention and therapy. This article provides an overview of the relationship between the gut microbiome and CRC, explores the mechanisms of colorectal tumorigenesis, and discusses the potential of bacterial species as clinical biomarkers.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2023)
Article
Oncology
Elyse R. Park, Sarah E. Skurla, Grelda Yazmin Juarez Caballero, Emily R. Friedman, Colin Ponzani, Robert Wallace, Jennifer Malin, Nancy L. Keating
Summary: This study examined the smoking rates and factors associated with continued smoking among lung and colorectal cancer survivors during long-term follow-up. The findings revealed that a significant proportion of lung and colorectal cancer survivors continued to smoke combustible cigarettes even after a long period of survivorship. Factors such as being male, younger, not married or partnered, having certain types of insurance, experiencing more depression symptoms, smoking more cigarettes per day, and having a history of lung disease were independently associated with continued smoking. These findings have implications for the development of tobacco treatment programs for cancer patients and survivors.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Medicine, General & Internal
Robert Siegel, Ricardo Niklas Werner, Stephan Koswig, Matthew Gaskins, Claus Roedel, Felix Aigner
Summary: The study provides detailed information on the development of the guidelines for the treatment of anal cancer. It recommends chemoradiotherapy as the standard treatment for stages II-III, with a suggestion against biopsy in complete clinical response. For stage IV anal cancer, there are only open recommendations, urging further research in this area.
DEUTSCHES ARZTEBLATT INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Cristina Bezzio, Gianpiero Manes, Mario Schettino, Ilaria Arena, Germana de Nucci, Cristina Della Corte, Massimo Devani, Enzo Mandelli, Daniela Morganti, Barbara Omazzi, Lucienne Pellegrini, Desiree Picascia, Davide Redaelli, Raffaella Reati, Simone Saibeni
Summary: IBD prevalence in asymptomatic adults is low, with majority having mild disease, though some may require biologic therapy.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Oncology
B. Keam, J-P Machiels, H. R. Kim, L. Licitra, W. Golusinski, V Gregoire, Y. G. Lee, C. Belka, Y. Guo, S. J. Rajappa, M. Tahara, M. Azrif, M. K. Ang, M-H Yang, C-H Wang, Q. S. Ng, W. I. Wan Zamaniah, N. Kiyota, S. Babu, K. Yang, G. Curigliano, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis
Summary: ESMO and KSMO convened a special virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider potential ethnic differences in Asian patients' treatment of SCCs of the head and neck. These guidelines represent consensus opinions from experts across Asia and provide expert recommendations for the diagnosis, treatment, and management of patients with SCC of the oral cavity, larynx, oropharynx, and hypopharynx.
Article
Gastroenterology & Hepatology
Tetsuhide Ito, Toshihiko Masui, Izumi Komoto, Ryuichiro Doi, Robert Y. Osamura, Akihiro Sakurai, Masafumi Ikeda, Koji Takano, Hisato Igarashi, Akira Shimatsu, Kazuhiko Nakamura, Yuji Nakamoto, Susumu Hijioka, Koji Morita, Yuichi Ishikawa, Nobuyuki Ohike, Atsuko Kasajima, Ryoji Kushima, Motohiro Kojima, Hironobu Sasano, Satoshi Hirano, Nobumasa Mizuno, Taku Aoki, Takeshi Aoki, Takao Ohtsuka, Tomoyuki Okumura, Yasutoshi Kimura, Atsushi Kudo, Tsuyoshi Konishi, Ippei Matsumoto, Noritoshi Kobayashi, Nao Fujimori, Yoshitaka Honma, Chigusa Morizane, Shinya Uchino, Kiyomi Horiuchi, Masanori Yamasaki, Jun Matsubayashi, Yuichi Sato, Masau Sekiguchi, Shinichi Abe, Takuji Okusaka, Mitsuhiro Kida, Wataru Kimura, Masao Tanaka, Yoshiyuki Majima, Robert T. Jensen, Koichi Hirata, Masayuki Imamura, Shinji Uemoto
Summary: Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical manifestations. Accurate pathological classification and determination of tumor characteristics are crucial for selecting appropriate treatment strategies. The revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) provide comprehensive directions for the management of NENs, incorporating new evidence and updated concepts.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Hematology
Brian Fulton, Riyaz Bashir, Mitchell D. Weinberg, Vladimir Lakhter, Parth Rali, Steve Pugliese, Jay Giri, Taisei Kobayashi
Summary: High-risk acute pulmonary embolism (PE) is a major cause of cardiovascular morbidity and mortality worldwide. Anticoagulant therapy and systemic thrombolysis have been the standard medical treatments for these patients, but recent guidelines reserve advanced therapies for cases where thrombolysis plus anticoagulation fails. The lack of prospective, randomized studies has led to significant variation in treatment approaches. A standardized approach to treatment, including early risk stratification and a multidisciplinary team approach, is crucial for improving outcomes. With the development of novel therapies and mechanical circulatory support systems, a standardized approach may now be possible.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Article
Oncology
S. -A. Im, A. Gennari, Y. H. Park, J. H. Kim, Z. -F. Jiang, S. Gupta, T. H. Fadjari, K. Tamura, M. Y. Mastura, M. L. T. Abesamis-Tiambeng, E. H. Lim, C. -H. Lin, A. Sookprasert, N. Parinyanitikul, L. -M. Tseng, S. -C. Lee, P. Caguioa, M. Singh, Y. Naito, R. A. Hukom, B. K. Smruti, S. -S. Wang, S. B. Kim, K. -H. Lee, H. K. Ahn, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis, G. Curigliano, N. Harbeck
Summary: The most recent version of the ESMO Clinical Practice Guidelines for metastatic breast cancer was published in 2021. In 2022, a special hybrid guidelines meeting was held to adapt these guidelines to the Asian context, with input from Asian oncology societies. The aim is to provide harmonized management of MBC patients across Asia.